Hsbc Holdings PLC Purchases 130,108 Shares of Halozyme Therapeutics, Inc. $HALO

Key Points

• HSBC significantly increased its Halozyme Therapeutics position by 130,108 shares, a 452.1% rise, bringing its holdings to 158,889 shares worth approximately $12.45 million. Institutional investors collectively own 97.79% of the company.
• Halozyme reported stronger-than-expected quarterly results, with EPS of $2.28 versus the $1.79 consensus estimate and revenue of $481 million, up 47.7% year over year. The company issued fiscal 2026 EPS guidance of $8.65–$9.00.
• Analyst sentiment remains favorable, with nine Buy ratings and a consensus “Moderate Buy” rating, although the average price target of $91.20 is below the reported share price of $108.31. Insiders sold 32,478 shares worth roughly $3.08 million over the past three months.

Hsbc Holdings PLC grew its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 452.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 158,889 shares of the biopharmaceutical company's stock after acquiring an additional 130,108 shares during the period. Hsbc Holdings PLC owned about 0.14% of Halozyme Therapeutics worth $12,447,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the company. Measured Wealth Private Client Group LLC increased its position in Halozyme Therapeutics by 51.5% during the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 124 shares during the last quarter. Abel Hall LLC increased its holdings in shares of Halozyme Therapeutics by 4.2% during the 4th quarter. Abel Hall LLC now owns 3,216 shares of the biopharmaceutical company's stock worth $216,000 after acquiring an additional 129 shares during the last quarter. StoneX Group Inc. increased its holdings in shares of Halozyme Therapeutics by 3.8% during the 4th quarter. StoneX Group Inc. now owns 3,650 shares of the biopharmaceutical company's stock worth $246,000 after acquiring an additional 132 shares during the last quarter. Twin Capital Management Inc. raised its stake in Halozyme Therapeutics by 1.4% in the 1st quarter. Twin Capital Management Inc. now owns 11,422 shares of the biopharmaceutical company's stock valued at $738,000 after acquiring an additional 161 shares during the period. Finally, Coldstream Capital Management Inc. raised its stake in Halozyme Therapeutics by 1.9% in the 3rd quarter. Coldstream Capital Management Inc. now owns 8,914 shares of the biopharmaceutical company's stock valued at $654,000 after acquiring an additional 165 shares during the period. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Trading Down 1.7%

Shares of Halozyme Therapeutics stock opened at $108.31 on Wednesday. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. The firm has a 50-day moving average of $92.02 and a 200-day moving average of $76.25. Halozyme Therapeutics, Inc. has a 52-week low of $61.22 and a 52-week high of $111.15. The stock has a market cap of $12.29 billion, a PE ratio of 32.33, a PEG ratio of 0.43 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, topping analysts' consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. During the same period last year, the firm earned $1.54 earnings per share. Halozyme Therapeutics's revenue for the quarter was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 7.98 EPS for the current year.

Insider Activity

In other news, Director Mahesh Krishnan sold 7,304 shares of the company's stock in a transaction on Monday, June 29th. The stock was sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the sale, the director directly owned 14,462 shares in the company, valued at approximately $1,084,650. This represents a 33.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $102.80, for a total value of $167,152.80. Following the sale, the director directly owned 40,418 shares in the company, valued at approximately $4,154,970.40. This trade represents a 3.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 32,478 shares of company stock worth $3,076,604. 2.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts have issued reports on HALO shares. Weiss Ratings raised Halozyme Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a report on Monday, August 31st. UBS Group reiterated a "buy" rating and issued a $90.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Benchmark restated a "buy" rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Leerink Partners upgraded shares of Halozyme Therapeutics from a "market perform" rating to an "outperform" rating and raised their target price for the stock from $83.00 to $110.00 in a research note on Friday, August 7th. Finally, Citizens Jmp lifted their target price on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a "market outperform" rating in a report on Friday, August 7th. Nine research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Halozyme Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $91.20.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.